Popular Trials
Cannabinoid
Cannabidiol for Dementia
The major purpose of this study is to assess the efficacy of CBD on motor symptoms of Parkinson's Disease (PD), and secondarily to study the safety and tolerability of CBD and other efficacy, particularly regarding tremor in PD. The study has been powered to detect a clinically significant reduction in Movement Disorder Society (MDS) Unified Parkinson's Disease Rating Scale (UPDRS) Part III motor scores. This is a 1:1 parallel, double-blind, randomized controlled trial (RCT) with 60 participants. The investigators will be recruiting up to 75 participants; the goal is to have 60 participants (30 in CBD group and 30 in placebo group) complete the study. The study drug is obtained from the National Institute on Drug Abuse (NIDA).
Behavioural Intervention
Walking Program + mHealth for Parkinson's Disease
This trial is testing the benefits of a walking program, exercises to improve walking, and cognitive-behavioral strategies delivered using mobile health technology for people with Parkinson disease.
Popular Filters
Trials for Parkinson's Disease Patients
Non-invasive Brain Stimulation
tDCS for Cognitive Impairment in Parkinson's Disease
This trial aims to use a novel personalized network analysis approach to elucidate the mechanisms of the effect of tDCS on cognitive dysfunction in non-demented PD patients.
Mucolytic Agent
Ambroxol for Parkinson's Disease Dementia
This trial tests if Ambroxol, a safe over-the-counter medication, can help people with Parkinson's Disease Dementia by increasing an enzyme that reduces harmful proteins in the brain. The goal is to see if it improves memory and movement problems. Ambroxol has been shown to be safe and well tolerated in previous studies.
Behavioural Intervention
Physical Therapy + Medication for Parkinson's Disease
This trial will compare physical therapy alone to physical therapy plus medication (either low dose methylphenidate or atomoxetine) to see if the addition of medication leads to more improvement in gait and balance in patients with Parkinson disease.
Dopamine Precursor
Continuous Subcutaneous Infusion of Levodopa/Carbidopa for Parkinson's Disease
This trial tests a pump that delivers medication under the skin for patients with advanced Parkinson's Disease. The treatment aims to improve movement symptoms by increasing dopamine levels in the brain. This method has been used for many years to manage motor complications in advanced Parkinson's Disease.
Trials for PD Patients
Non-invasive Brain Stimulation
tDCS for Cognitive Impairment in Parkinson's Disease
This trial aims to use a novel personalized network analysis approach to elucidate the mechanisms of the effect of tDCS on cognitive dysfunction in non-demented PD patients.
Mucolytic Agent
Ambroxol for Parkinson's Disease Dementia
This trial tests if Ambroxol, a safe over-the-counter medication, can help people with Parkinson's Disease Dementia by increasing an enzyme that reduces harmful proteins in the brain. The goal is to see if it improves memory and movement problems. Ambroxol has been shown to be safe and well tolerated in previous studies.
Behavioural Intervention
Physical Therapy + Medication for Parkinson's Disease
This trial will compare physical therapy alone to physical therapy plus medication (either low dose methylphenidate or atomoxetine) to see if the addition of medication leads to more improvement in gait and balance in patients with Parkinson disease.
Dopamine Precursor
Continuous Subcutaneous Infusion of Levodopa/Carbidopa for Parkinson's Disease
This trial tests a pump that delivers medication under the skin for patients with advanced Parkinson's Disease. The treatment aims to improve movement symptoms by increasing dopamine levels in the brain. This method has been used for many years to manage motor complications in advanced Parkinson's Disease.
Trials With No Placebo
Behavioural Intervention
Physical Therapy + Medication for Parkinson's Disease
This trial will compare physical therapy alone to physical therapy plus medication (either low dose methylphenidate or atomoxetine) to see if the addition of medication leads to more improvement in gait and balance in patients with Parkinson disease.
Dopamine Precursor
Continuous Subcutaneous Infusion of Levodopa/Carbidopa for Parkinson's Disease
This trial tests a pump that delivers medication under the skin for patients with advanced Parkinson's Disease. The treatment aims to improve movement symptoms by increasing dopamine levels in the brain. This method has been used for many years to manage motor complications in advanced Parkinson's Disease.
Nerve Grafts + DBS Surgery for Parkinson's Disease
This trial tests the safety of implanting a patient's own nerve tissue into their brain during surgery for Parkinson's disease. The goal is to use natural substances from the nerve tissue to help protect and repair brain cells affected by the disease.
Behavioural Intervention
CranioSacral Therapy for Parkinson's Disease
This trial is studying the effect of CranioSacral Integrative therapy on Parkinson's Diseased Patients. This therapy is given biweekly for 3 months, and the investigators expect to see a positive change in the symptoms of the patients.
View More Related Trials
Frequently Asked Questions
Introduction to parkinson
What are the top hospitals conducting parkinson research?
While clinical trials for [Parkinson's disease](https://www.withpower.com/clinical-trials/parkinson's-disease) may still be in their early stages, several top hospitals are leading the way in advancing our understanding and treatment of this complex condition. In Toronto, the Toronto Western Hospital is currently conducting six active Parkinson's trials, showcasing its commitment to finding innovative solutions for patients. Moving south to Chicago, Rush University Medical Center has five ongoing trials focused solely on Parkinson's disease. This renowned institution is at the forefront of research and has made significant strides in improving the lives of those affected by this neurodegenerative disorder.
On the West Coast, Stanford University also prioritizes Parkinson's research with four active clinical trials. The expertise and dedication of its medical professionals contribute to groundbreaking advancements that offer hope to individuals living with Parkinson's. Meanwhile, even away from major cities like Chicago or Toronto, specialized centers like the Parkinson's Disease and Movement Disorders Center of Boca Raton are making a difference too. They're actively involved in three ongoing clinical trials dedicated exclusively to exploring new treatments for patients.
Lastly, Northwestern University in Chicago deserves recognition for its contributions as well; it is currently running three active clinical studies focused on treating and managing symptoms associated with Parkinson’s disease while earnestly working towards breakthroughs that could revolutionize how we approach this neurological condition.
These hospitals are not only providing cutting-edge care but also offering opportunities for patients to participate in ground-breaking research studies that have enormous potential implications worldwide- an exciting prospect considering there remain no previously concluded records available within these institutions specifically targeting parkinsonism thus far! Such initiatives pave way forward creating brighter outlooks against Parkinons' fight
Which are the best cities for parkinson clinical trials?
When it comes to clinical trials for [Parkinson's disease](https://www.withpower.com/clinical-trials/parkinson's-disease), several cities are at the forefront of research and advancement. New york, New York leads the pack with 19 active trials exploring treatments such as BIIB122, ExAblate Pallidotomy, and LY3884961. Philadelphia, Pennsylvania closely follows with 17 ongoing studies focused on ABBV-951, Investigational Treatment 1, and RO7486967 Arm. Additionally, Chicago in Illinois is conducting 14 active trials investigating ABBV-951, BIIB122, and Tavapadon. Lastly Los Angeles in California and Tampa in Florida both have 13 active trials each studying various potential breakthroughs like Movement task and IkT-148009 respectively. These cities offer individuals with Parkinson's disease access to cutting-edge clinical trials that may lead to new treatment options and improved quality of life.
Which are the top treatments for parkinson being explored in clinical trials?
Clinical trials are at the forefront of [Parkinson's disease](https://www.withpower.com/clinical-trials/parkinson's-disease) research, with several promising treatments currently being explored. One standout option is gene therapy, which aims to correct genetic abnormalities associated with the condition. Another avenue under investigation is deep brain stimulation (DBS), where electrodes are implanted in specific regions of the brain to alleviate symptoms. Additionally, researchers are looking into novel medications that target specific pathways involved in Parkinson's progression, providing hope for improved treatment options in the future.
What are the most recent clinical trials for parkinson?
Exciting advancements in [Parkinson's disease](https://www.withpower.com/clinical-trials/parkinson's-disease) research are underway through recent clinical trials. One promising trial is evaluating the effectiveness of Waitlist Couple Pairs Parkinson's Group, a Phase 2 study that aims to improve outcomes for patients with Parkinson's. Another Phase 2 trial focuses on IkT-148009 and its potential benefits in managing the symptoms of this neurodegenerative disorder. In addition, Terazosin therapy is being investigated in a Phase 2 trial to assess its efficacy as a treatment option. These studies offer hope for improved quality of life and better management strategies for individuals living with Parkinson's disease.
What parkinson clinical trials were recently completed?
Several recent clinical trials have made significant advancements in the field of [Parkinson's disease](https://www.withpower.com/clinical-trials/parkinson's-disease) research. Notably, a trial sponsored by AbbVie completed in September 2021 focused on evaluating the efficacy of ABBV-951, a potential treatment option for this neurodegenerative disorder. Additionally, Biogen concluded their study on BIIB054, another promising therapy for Parkinson's disease, in June 2021. These important milestones highlight the ongoing efforts to discover innovative treatments that could potentially improve the lives of individuals living with Parkinson's disease.